Skip to main content
SpringerLink
Log in

Overview of Pancreatic Masses and Cystic Lesions

  • Chapter
  • First Online:
Endoscopic Ultrasound Management of Pancreatic Lesions

Abstract

A wide spectrum of benign and malignant diseases can produce a mass in the pancreas; these diseases can be solid (ductal adenocarcinoma, chronic pancreatitis, endocrine tumor) or cystic. The most important question is whether or not it is a malignant or a benign tumor; whenever possible, in the majority of the cases that are fit for treatment, histological confirmation of the diagnosis of malignancy is necessary. The major interest in routine clinical practice is in diagnosing and treating benign and malignant tumors; a systematic classification of pancreatic masses has recently been reported by the World Health Organization. Pancreatic neoplasms originate from epithelial cells, neuroendocrine cells, and mesenchymal tumors; the pancreas can also be involved in lymphomas and solid tumors of distant organs. The aim of this review was to describe the clinical signs of solid and cystic lesions as well as the imaging aspects which help the clinician to reach a diagnosis. Regarding treatment, patients with solid lesions should be resected. However, the medical and radiological follow-up is important to detect malignant transformation in those affected by cystic lesions, such as branch-duct intraductal papillary mucinous neoplasia (IPMNs) who do not need immediate surgery but are fit for surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Digestive system tumours WHO classification of tumours. vol 1, 5th ed. Lyon; 2019.

    Google Scholar 

  2. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of endocrine organs, vol. 1. Lyon: IARC WHO Classification of Tumours; 2017.

    Google Scholar 

  3. Pezzilli R. Asymptomatic lesions of the pancreas: an overview. J Gastroenterol Hepatol Res. 2014;3:1216–9.

    Article  Google Scholar 

  4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

    Article  PubMed  Google Scholar 

  5. Laffan TA, Horton KM, Klein AP, Berlanstein B, Siegelman SS, Kawamoto S, Johnson PT, Fishman EK, Hruban RH. Prevalence of unsuspected pancreatic cysts on MDCT. Am J Roentgenol. 2008;191:802–7.

    Article  Google Scholar 

  6. de Jong K, Nio CY, Hermans JJ, Dijkgraaf MG, Gouma DJ, van Eijck CH, van Heel E, Klass G, Fockens P, Bruno MJ. High pre- valence of pancreatic cysts detected by screening magnetic resonance imaging examinations. Clin Gastroenterol Hepatol. 2010;8:806–11.

    Article  PubMed  Google Scholar 

  7. de Oliveira PB, Puchnick A, Szejnfeld J, Goldman SM. Prevalence of incidental pancreatic cysts on 3 tesla magnetic resonance. PLoS One. 2015;10:e0121317.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Lee HW, Lee SK, Jun JH, Song TJ, Park DH, Lee SS, Seo DW, Kim MH. Timing and clinical features of spontaneous decrease in size of small pancreatic cystic lesions without high-risk stigmata. Gut Liver. 2020;14(2):248–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Strang AM, Lockhart ME, Kenney PJ, Amling CL, Urban DA, El-Galley R, Burns JR, Colli JL, Hammontree LN, Kolettis PN. Computer-ized tomographic angiography for renal donor evaluation leads to a higher exclusion rate. J Urol. 2007;177:1826–9.

    Article  PubMed  Google Scholar 

  10. Pitts A, Nissen NN, Waxman A, Yu R. Unsuspected fluorodeoxyglucose positron emission tomography (FDG-PET)–positive pancreatic lesions. Pancreas. 2013;42:1191–3.

    Article  PubMed  Google Scholar 

  11. Winter JM, Cameron JL, Lillemoe KD, Campbell KA, Chang D, Riall TS, Coleman J, Sauter PK, Canto M, Hruban RH, Schulick RD, Choti MA, Yeo CJ. Periampullary and pancreatic incidentaloma: a single institution’s experience with an increasingly common diagnosis. Ann Surg. 2006;243:673–80.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Flanders TY, Foulkes WD. Pancreatic adenocarcinoma: epidemiology and genetics. J Med Genet. 1996;33:889–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Santo E, Bar-Yishay I. Pancreatic solid incidentalomas. Endosc Ultrasound. 2017;6:S99–103.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607–20.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Sachs T, Pratt WB, Callery MP, Vollmer CM Jr. The incidental asymptomatic pancreatic lesion: nuisance or threat? J Gastrointest Surg. 2009;13:405–15.

    Article  PubMed  Google Scholar 

  16. Young K, Iyer R, Morganstein D, Chau I, Cunningham D, Starling N. Pancreatic neuroendocrine tumors: a review. Future Oncol. 2015;11:853–64.

    Article  CAS  PubMed  Google Scholar 

  17. Porta M, Fabregat X, Malats N, Guarner L, Carrato A, de Miguel A, et al. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol. 2005;7:189–97.

    Article  PubMed  Google Scholar 

  18. Freelove R, Walling AD. Pancreatic cancer: diagnosis and management. Am Fam Physician. 2006;73:485–92.

    PubMed  Google Scholar 

  19. Pezzilli R, Cucchetti A, Calculli L. Comparison of clinical data and scores of quality of life, anxiety, and depression in patients with different types of intraductal papillary mucinous neoplasms: a prospective study. Pancreas. 2017;46:1029–34.

    Article  PubMed  Google Scholar 

  20. Pezzilli R, Calculli L. Branch-type intraductal papillary mucinous neoplasm of the pancreas: clinically and patient-reported outcomes. Pancreas. 2015;44:221–6.

    Article  CAS  PubMed  Google Scholar 

  21. Buscarini E, Pezzilli R, Cannizzaro R, De Angelis C, Gion M, Morana G, Zamboni G, Arcidiacono P, Balzano G, Barresi L, Basso D, Bocus P, Calculli L, Capurso G, Canzonieri V, Casadei R, Crippa S, D’Onofrio M, Frulloni L, Fusaroli P, Manfredi G, Pacchioni D, Pasquali C, Rocca R, Ventrucci M, Venturini S, Villanacci V, Zerbi A, Falconi M. Italian consensus guidelines for the diagnostic work-up and follow-up of cystic pancreatic neoplasms. Dig Liver Dis. 2014;46:479–93.

    Article  PubMed  Google Scholar 

  22. Keane MG, Horsfall L, Rait G, Pereira SP. A case-control study comparing the incidence of early symptoms in pancreatic and biliary tract cancer. BMJ Open. 2014;4:e005720.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an over- view. Nat Rev Gastroenterol Hepatol. 2009;6:699–708.

    Article  PubMed  Google Scholar 

  24. Furukawa H, Okada S, Saisho H, Ariyama J, Karasawa E, Nakaizumi A, et al. Clinicopathologic features of small pancreatic adenocarcinoma: a collective study. Cancer. 1996;78:986–90.

    Article  CAS  PubMed  Google Scholar 

  25. D’Haese JG, Hartel M, Demir IE, Hinz U, Bergmann F, Büchler MW, Friess H, Ceyhan GO. Pain sensation in pancreatic diseases is not uniform: the different facets of pancreatic pain. World J Gastroenterol. 2014;20:9154–61.

    PubMed  PubMed Central  Google Scholar 

  26. Ceyhan GO, Bergmann F, Kadihasanoglu M, Altintas B, Demir IE, Hinz U, Müller MW, Giese T, Büchler MW, Giese NA, Friess H. Pancreatic neuropathy and neuropathic pain. A comprehensive pathomorphological study of 546 cases. Gastroenterology. 2009;136:177–86.

    Article  PubMed  Google Scholar 

  27. Müller MW, Friess H, Köninger J, Martin D, Wente MN, Hinz U, Ceyhan GO, Blaha P, Kleeff J, Büchler MW. Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas. Am J Surg. 2008;195:221–8.

    Article  PubMed  Google Scholar 

  28. Okusaka T, Okada S, Ueno H, Ikeda M, Shimada K, Yamamoto J, Kosuge T, Yamasaki S, Fukushima N, Sakamoto M. Abdominal pain in patients with resectable pancreatic cancer with reference to clinicopathologic findings. Pancreas. 2001;22:279–84.

    Article  CAS  PubMed  Google Scholar 

  29. Holly EA, Chaliha I, Bracci PM, Gautam M. Signs and symptoms of pancreatic cancer: a population-based case-control study in the San Francisco Bay area. Clin Gastroenterol Hepatol. 2004;2:510–7.

    Article  PubMed  Google Scholar 

  30. Pezzilli R. Applicability of a checklist for the diagnosis and treatment of severe exocrine pancreatic insufficiency: a survey on the management of pancreatic maldigestion in Italy. Panminerva Med. 2016;58:245–52.

    PubMed  Google Scholar 

  31. Fearon KC, Baracos VE. Cachexia in pancreatic cancer: new treatment options and measures of success. HPB (Oxford). 2010;12:323–4.

    Article  Google Scholar 

  32. Bachmann J, Heiligensetzer M, Krakowski-Roosen H, Büchler MW, Friess H, Martignoni ME. Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg. 2008;12:1193–201.

    Article  PubMed  Google Scholar 

  33. Kyle UG, Pirlich M, Lochs H, Schuetz T, Pichard C. Increased length of hospital stay in underweight and overweight patients at hospital admission: a controlled population study. Clin Nutr. 2005;24(1):133–42.

    Article  PubMed  Google Scholar 

  34. Gullo L, Pezzilli R, Morselli-Labate AM, Italian Pancreatic Cancer Study Group. Diabetes and the risk of pancreatic cancer. N Engl J Med. 1994;331:81–4.

    Article  CAS  PubMed  Google Scholar 

  35. Gullo L, Pezzilli R. Diabetes and pancreatic cancer. Pancreas. 2004;28:451.

    Article  PubMed  Google Scholar 

  36. Gallo M, Ruggeri RM, Muscogiuri G, Pizza G, Faggiano A, Colao A. Diabetes and pancreatic neuroendocrine tumours: which interplays, if any? Cancer Treat Rev. 2018;67:1–9.

    Article  PubMed  Google Scholar 

  37. Barkin JS, Goldstein JA. Diagnostic and therapeutic approach to pancreatic cancer. Biomed Pharmacother. 2000;54:400–9.

    Article  CAS  PubMed  Google Scholar 

  38. European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut. 2018;67:789–804.

    Article  Google Scholar 

  39. Hackert T, Fritz S, Klauss M, Bergmann F, Hinz U, Strobel O, Schneider L, Büchler MW. Main-duct intraductal papillary mucinous neoplasm: high cancer risk in duct diameter of 5 to 9 mm. Ann Surg. 2015;262:875–80.

    Article  PubMed  Google Scholar 

  40. Morales-Oyarvide V, Mino-Kenudson M, Ferrone CR, Gonzalez-Gonzalez LA, Warshaw AL, Lillemoe KD, Fernández-del Castillo C. Acute pancreatitis in intraductal papillary mucinous neoplasms: a common predictor of malignant intestinal subtype. Surgery. 2015;158:1219–25.

    Article  PubMed  Google Scholar 

  41. Konings IC, Harinck F, Poley JW, Aalfs CM, van Rens A, Krak NC, Wagner A, Nio CY, Sijmons RH, van Dullemen HM, Vleggaar FP, Ausems MG, Fockens P, van Hooft JE, Bruno MJ. Prevalence and progression of pancreatic cystic precursor lesions differ between groups at high risk of developing pancreatic cancer. Pancreas. 2017;46:28–34.

    Article  CAS  PubMed  Google Scholar 

  42. Capurso G, Boccia S, Salvia R, Del Chiaro M, Frulloni L, Arcidiacono PG, Zerbi A, Manta R, Fabbri C, Ventrucci M, Tarantino I, Piciucchi M, Carnuccio A, Boggi U, Leoncini E, Costamagna G, Delle Fave G, Pezzilli R, Bassi C, Larghi A. Risk factors for intraductal papillary mucinous neoplasm (IPMN) of the pancreas: a multicentre case-control study. Am J Gastroenterol. 2013;108:1003–9.

    Article  PubMed  Google Scholar 

  43. Ohtsuka T, Kono H, Nagayoshi Y, Mori Y, Tsutsumi K, Sadakari Y, Takahata S, Morimatsu K, Aishima S, Igarashi H, Ito T, Ishigami K, Nakamura M, Mizumoto K, Tanaka M. An increase in the number of predictive factors augments the likelihood of malignancy in branch duct intraductal papillary mucinous neoplasm of the pancreas. Surgery. 2012;151:76–83.

    Article  PubMed  Google Scholar 

  44. Perez-Johnston R, Narin O, Mino-Kenudson M, Ingkakul T, Warshaw AL, Fernandez-Del Castillo C, Sahani VD. Frequency and significance of calcification in IPMN. Pancreatology. 2013;13:43–7.

    Article  CAS  PubMed  Google Scholar 

  45. Fritz S, Hackert T, Hinz U, Hartwig W, Büchler MW, Werner J. Role of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary mucinous neoplasm of the pancreas. Br J Surg. 2011;98:104–10.

    Article  CAS  PubMed  Google Scholar 

  46. Chang YT, Tien YW, Jeng YM, Yang CY, Liang PC, Wong JM, Chang MC. Overweight increases the risk of malignancy in patients with pancreatic mucinous cystic neoplasms. Medicine (Baltimore). 2015;94:e797.

    Article  Google Scholar 

  47. Mughetti M, Calculli L, Chiesa AM, Ciccarese F, Rrusho O, Pezzilli R. Implications and issues related to familial pancreatic cancer: a cohort study of hospitalized patients. BMC Gastroenterol. 2016;16:6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  48. Paiella S, Capurso G, Cavestro GM, Butturini G, Pezzilli R, Salvia R, Signoretti M, Crippa S, Carrara S, Frigerio I, Bassi C, Falconi M, Iannicelli E, Giardino A, Mannucci A, Laghi A, Laghi L, Frulloni L, Zerbi A. Results of first-round of surveillance in individuals at high-risk of pancreatic cancer from the AISP (Italian Association for the Study of the Pancreas) Registry. Am J Gastroenterol. 2019;114:665–70.

    Article  PubMed  Google Scholar 

  49. Takeuchi S, Doi M, Ikari N, Yamamoto M, Furukawa T. Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma. Sci Rep. 2018;8(1):8105.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  50. Mafficini A, Scarpa A. Genetics and epigenetics of gastroenteropancreatic neuroendocrine neoplasms. Endocr Rev. 2019;40:506–36.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Pezzilli R, Casadei R, Calculli L, Santini D, Morselli-Labate AM, NeoPan Study Group. Serum determination of CA 19-9 in diagnosing pancreatic cancer: an obituary. Dig Liver Dis. 2010;42:73–4.

    Article  CAS  PubMed  Google Scholar 

  52. Pezzilli R, Calculli L, Melzi d’Eril G, Barassi A. Serum tumor markers not useful in screening patients with pancreatic mucinous cystic lesions associated with malignant changes. Hepatobiliary Pancreat Dis Int. 2016;15:553–7.

    Article  PubMed  Google Scholar 

  53. Pleskow DK, Berger HJ, Gyves J, Allen E, McLean A, Podolsky DK. Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med. 1989;110:704–9.

    Article  CAS  PubMed  Google Scholar 

  54. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol. 1990;85:350–5.

    CAS  PubMed  Google Scholar 

  55. Maithel SK, Maloney S, Winston C, Gönen M, D’Angelica MI, Dematteo RP, Jarnagin WR, Brennan MF, Allen PJ, Preoperative CA. 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2008;15:3512–20.

    Article  PubMed  Google Scholar 

  56. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC Jr. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313–27.

    Article  CAS  PubMed  Google Scholar 

  57. van den Bosch RP, van Eijck CH, Mulder PG, Jeekel J. Serum CA19-9 determination in the management of pancreatic cancer. Hepato-gastroenterol. 1996;43:710–3.

    Google Scholar 

  58. Smith RA, Bosonnet L, Ghaneh P, Raraty M, Sutton R, Campbell F, Neoptolemos JP. Preoperative CA19-9 levels and lymph node ratio are independent predictors of survival in patients with resected pancreatic ductal adenocarcinoma. Dig Surg. 2008;25:226–32.

    Article  CAS  PubMed  Google Scholar 

  59. Zhang S, Wang Y-M, Sun C-D, Lu Y, Wu L-Q. Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma. World J Gastroenterol. 2008;14:3750–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Waraya M, Yamashita K, Katagiri H, Ishii K, Takahashi Y, Furuta K, Watanabe M. Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer. Ann Surg Oncol. 2009;16:1231–40.

    Article  PubMed  Google Scholar 

  61. Campana D, Nori F, Piscitelli L, Morselli-Labate AM, Pezzilli R, Corinaldesi R, Tomassetti P. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol. 2007;25:1967–73.

    Article  CAS  PubMed  Google Scholar 

  62. Pezzilli R, Migliori M, Morselli-Labate AM, Campana D, Ventrucci M, Tomassetti P, Corinaldesi R. Diagnostic value of tumor M2-pyruvate kinase in neuroendocrine tumors. A comparative study with chromogranin A. Anticancer Res. 2003;23:2969–72.

    CAS  PubMed  Google Scholar 

  63. Serra C, Felicani C, Mazzotta E, Piscitelli L, Cipollini ML, Tomassetti P, Pezzilli R, Casadei R, Morselli-Labate AM, Stanghellini V, Corinaldesi R, De Giorgio R. Contrast-enhanced ultrasound in the differential diagnosis of exocrine versus neuroendocrine pancreatic tumors. Pancreas. 2013;42:871–7.

    Article  CAS  PubMed  Google Scholar 

  64. Pezzilli R, Serra C, Calculli L, Ferroni F, Iammarino MT, Casadei R. Three-dimensional contrast-enhanced ultrasonography of intraductal papillary mucinous neoplasms of the pancreas: a comparison with magnetic resonance imaging. Pancreas. 2013;42:1164–8.

    Article  CAS  PubMed  Google Scholar 

  65. Calculli L, Casadei R, Amore B, Albini Riccioli L, Minni F, Caputo M, Marrano D, Gavelli G. The usefulness of spiral Computed Tomography and colour-Doppler ultrasonography to predict portal-mesenteric trunk involvement in pancreatic cancer. Radiol Med. 2002;104:307–15.

    PubMed  Google Scholar 

  66. Konda VJ, Meining A, Jamil LH, Giovannini M, Hwang JH, Wallace MB, Chang KJ, Siddiqui UD, Hart J, Lo SK, Saunders MD, Aslanian HR, Wroblewski K, Waxman I. A pilot study of in vivo identification of pancreatic cystic neoplasms with needle-based confocal laser endomicroscopy under endosonographic guidance. Endoscopy. 2013;45:1006–13.

    Article  PubMed  Google Scholar 

  67. Bertani H, Pezzilli R, Pigò F, Bruno M, De Angelis C, Manfredi G, Delconte G, Conigliaro R, Buscarini E. LEOPARD study: Italian multicenter prospective study of pancreatic cystic lesions with confocal endomicroscopy: feasibility and safety evaluation. Endoscopy. 2019;51:42–3.

    Google Scholar 

  68. Barral M, Taouli B, Guiu B, Koh DM, Luciani A, Manfredi R, Vilgrain V, Hoeffel C, Kanematsu M, Soyer P. Diffusion-weighted MR imaging of the pancreas: current status and recommendations. Radiology. 2015;274:45–63.

    Article  PubMed  Google Scholar 

  69. Oláh A. Pancreatic head mass: what can be done? Diagnosis: surgery. JOP. 2001;1(3 Suppl):127–9.

    Google Scholar 

  70. Jais B, Rebours V, Malleo G, Salvia R, Fontana M, Maggino L, Bassi C, Manfredi R, Moran R, Lennon AM, Zaheer A, Wolfgang C, Hruban R, Marchegiani G, Fernández Del Castillo C, Brugge W, Ha Y, Kim MH, Oh D, Hirai I, Kimura W, Jang JY, Kim SW, Jung W, Kang H, Song SY, Kang CM, Lee WJ, Crippa S, Falconi M, Gomatos I, Neoptolemos J, Milanetto AC, Sperti C, Ricci C, Casadei R, Bissolati M, Balzano G, Frigerio I, Girelli R, Delhaye M, Bernier B, Wang H, Jang KT, Song DH, Huggett MT, Oppong KW, Pererva L, Kopchak KV, Del Chiaro M, Segersvard R, Lee LS, Conwell D, Osvaldt A, Campos V, Aguero Garcete G, Napoleon B, Matsumoto I, Shinzeki M, Bolado F, Fernandez JM, Keane MG, Pereira SP, Acuna IA, Vaquero EC, Angiolini MR, Zerbi A, Tang J, Leong RW, Faccinetto A, Morana G, Petrone MC, Arcidiacono PG, Moon JH, Choi HJ, Gill RS, Pavey D, Ouaïssi M, Sastre B, Spandre M, De Angelis CG, Rios-Vives MA, Concepcion-Martin M, Ikeura T, Okazaki K, Frulloni L, Messina O, Lévy P. Serous cystic neoplasm of the pancreas: a multinational study of 2622 patients under the auspices of the International Association of Pancreatology and European Pancreatic Club (European Study Group on Cystic Tumors of the Pancreas). Gut. 2016;65:305–12.

    Article  CAS  PubMed  Google Scholar 

  71. Tanaka M, Fernández-Del Castillo C, Kamisawa T, Jang JY, Levy P, Ohtsuka T, Salvia R, Shimizu Y, Tada M, Wolfgang CL. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017;17:738–53.

    Article  PubMed  Google Scholar 

  72. Vege SS, Ziring B, Jain R, Moayyedi P. American Gastroenterological Association Institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015;148:819–22.

    Article  PubMed  Google Scholar 

  73. Crippa S, Pezzilli R, Bissolati M, Capurso G, Romano L, Brunori MP, Calculli L, Tamburrino D, Piccioli A, Ruffo G, Fave GD, Falconi M. Active surveillance beyond 5 years is required for presumed branch-duct intraductal papillary mucinous neoplasms undergoing non-operative management. Am J Gastroenterol. 2017;112:1153–61.

    Article  PubMed  Google Scholar 

  74. Oyama H, Tada M, Takagi K, Tateishi K, Hamada T, Nakai Y, Hakuta R, Ijichi H, Ishigaki K, Kanai S, Kogure H, Mizuno S, Saito K, Saito T, Sato T, Suzuki T, Takahara N, Morishita Y, Arita J, Hasegawa K, Tanaka M, Fukayama M, Koike K. Long-term risk of malignancy in branch-duct intraductal papillary mucinous neoplasms. Gastroenterology. 2020;158(1):226–237.e5.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. San Carlo Hospital, Potenza, Italy

    Raffaele Pezzilli

Authors
  1. Raffaele Pezzilli
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy

    Antonio Facciorusso

  2. Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy

    Nicola Muscatiello

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Pezzilli, R. (2021). Overview of Pancreatic Masses and Cystic Lesions. In: Facciorusso, A., Muscatiello, N. (eds) Endoscopic Ultrasound Management of Pancreatic Lesions. Springer, Cham. https://doi.org/10.1007/978-3-030-71937-1_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-71937-1_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-71936-4

  • Online ISBN: 978-3-030-71937-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation